Clinical Trial Update: Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating desvenlafaxine succinate sustained-release (DVS SR) for pain in diabetic peripheral neuropathy was terminated, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy

Drugs mentioned

• Desvenlafaxine succinate sustained-release (DVS SR) (desvenlafaxine succinate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Diabetic Neuropathies, Pain | Phase 3 | Status: TERMINATED | Results posted: 2009-08-13